阿那曲唑和他莫昔芬对绝经后乳腺癌患者肝功能的影响

【摘要】 目的观察单独口服阿那曲唑和他莫昔芬对绝经后乳腺癌患者肝功能的影响。方法绝经后乳腺癌患者共14例。实验组患者7例,口服阿那曲唑;对照组患者7例,口服他莫昔芬。所有患者均服药3年。分别于服药前及服药后每6个月检测肝功能的血清学指标。结果两组患者ALT(P=0.038)和GGT(P=0.003)的均数随时间变化均有所下降,差别有统计学意义。口服他莫昔芬组患者AST的水平较口服阿那曲唑组患者的高,差别有统计学意义(P=0.023);而TBIL和AKP这两个指标水平则是口服阿那曲唑组高于口服他莫昔芬组,差别有统计学意义[TBIL(P=0.027)、AKP(P=0.047)];两组患者各监测指标的每次测量结果均数均在参考值范围之内。结论本次研究证据尚不足以证明阿那曲唑和他莫昔芬能够导致肝功能损伤,甚至引起脂肪肝。更多还原

【Abstract】 Object To 0bserve the effects of Anastrozole and Tamoxifen on the liver function in postmenopausal women with breast cancer.Methods There are 14 postmenopausal women with breast cancer who underwent adjuvant endocrine therapy.They were treated with oral Anastrozole(n=7) or oral Tamoxifen(n=7).We test and analyze the liver function in 3 years,using ALT,AST,TBIL,GGT and AKP,before and every half year.Results The results showed that the ALT mean(P =0.038) and GGT mean(P =0.003) were reduced in both the Anastrozole and Tamoxifen group,the difference was significant.In Anastrozole group,the levels of AST mean(P =0.023) TBIL mean(P =0.027) and AKP mean(P =0.047) were higher than the Tamoxifen group.However,the levels of the ALT mean(P =0.110) and GGT mean(P =0.277) had no significant.Conclusion The research was insufficient to prove that both the Anastrozole and the Tamoxifen had effect on the liver function in postmenopausal women with breast cancer.更多还原